Cargando…

Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia

PURPOSE: To evaluate the efficacy and tolerability of tamsulosin 0.4 mg once daily in Korean patients with symptomatic benign prostatic hyperplasia (BPH) and investigate whether tamsulosin 0.4 mg can improve symptoms in patients with refractory lower urinary tract symptoms (LUTS) who were previously...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Jae-Wook, Choi, Seock Hwan, Kim, Bum Soo, Kim, Tae-Hwan, Yoo, Eun Sang, Kim, Chun Il, Lee, Kyung Seop, Kwon, Tae Gyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151636/ https://www.ncbi.nlm.nih.gov/pubmed/21860769 http://dx.doi.org/10.4111/kju.2011.52.7.479

Ejemplares similares

Letter to the Editor: Commentary on “Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients”
por: Tae, Bum Sik, et al.
Publicado: (2017)

Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients
por: Kim, Su Jin, et al.
Publicado: (2017)

Beneficial Effect of Increasing the Dose of Tamsulosin to 0.4 mg in Japanese Patients with Benign Prostatic Hyperplasia
por: Hirose, Yasuhiko, et al.
Publicado: (2011)

Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction
por: Ahn, Sun Tae, et al.
Publicado: (2020)

The Authors Reply: Reply on “Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients”
por: Kim, Su Jin, et al.
Publicado: (2017)

Efficacy of 0.4 mg tamsulosin monotherapy in patients with moderate-to-severe lower urinary tract symptoms
por: Kang, Tae Wook, et al.
Publicado: (2021)

Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia
por: Soliman, Mohamed G., et al.
Publicado: (2023)

An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin
por: Yang, Pei-Shan, et al.
Publicado: (2018)

Evaluation of the pharmacokinetics and food effects of a novel formulation tamsulosin 0.4 mg capsule compared with a 0.2 mg capsule in healthy male volunteers
por: Ban, Mu Seong, et al.
Publicado: (2020)

Effects of Low-Dose Tamsulosin on Sexual Function in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
por: Kim, Sin Wook, et al.
Publicado: (2013)

Effects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia
por: Choi, Jae Hwi, et al.
Publicado: (2014)

Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy
por: Kang, Tae Wook, et al.
Publicado: (2020)

Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
por: Wang, Hui, et al.
Publicado: (2017)

Cost-Effectiveness of Tamsulosin, Doxazosin, and Terazosin in the Treatment of Benign Prostatic Hyperplasia
por: Ohsfeldt, Robert L., et al.
Publicado: (2004)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
por: Zhou, Zhongbao, et al.
Publicado: (2019)

A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia
por: Manjunatha, R., et al.
Publicado: (2016)

Efficacy of combination therapy with tamsulosin and zolpidem on nocturia in patients with benign prostatic hyperplasia
por: Miwa, Kousei, et al.
Publicado: (2011)

Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model
por: Choi, Bo Ram, et al.
Publicado: (2018)

Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial
por: Pande, Satabdi, et al.
Publicado: (2014)

Short-term Effect of Tamsulosin and Finasteride Monotherapy and their Combination on Nigerian Men with Benign Prostatic Hyperplasia
por: Odusanya, Benjamin O, et al.
Publicado: (2017)

Clinical characteristics of surgically managed patients with asymptomatic renal stones: Comparison of patients with symptomatic renal stones
por: Park, Dong Jin, et al.
Publicado: (2023)

A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil
por: POMPEO, A C L, et al.
Publicado: (2006)

Prostatic urethral length as a predictive factor for surgical treatment of benign prostatic hyperplasia: a prospective, multiinstitutional study
por: Kim, Bum Soo, et al.
Publicado: (2019)

Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats
por: Ko, Il-Gyu, et al.
Publicado: (2018)

Giant bilateral symptomatic adrenal myelolipomas manifested in an adult with congetnial adrenal hyperplasia
por: Kim, Yoo-Mi, et al.
Publicado: (2013)

Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia
por: Griwan, Mahavir Singh, et al.
Publicado: (2014)

Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis
por: Cai, Tong, et al.
Publicado: (2020)

Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial
por: Sebastianelli, Arcangelo, et al.
Publicado: (2019)

Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability
por: Barkin, Jack
Publicado: (2011)

Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin
por: Djavan, Bob, et al.
Publicado: (2011)

Risk factors for hypertensive attack during pheochromocytoma resection
por: Kwon, Se Yun, et al.
Publicado: (2016)

Obesity Is an Adverse Factor on Laparoscopic Radical Nephrectomy for T2 but Not T1 Renal Cell Carcinoma
por: Kwon, Se Yun, et al.
Publicado: (2011)

Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial
por: Shin, Yu Seob, et al.
Publicado: (2016)

Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting
por: Geitona, Maria, et al.
Publicado: (2014)

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia
por: Zhou, Rui, et al.
Publicado: (2023)

Impact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile Function
por: Seo, Deok Ha, et al.
Publicado: (2011)

Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia
por: Dimitropoulos, Konstantinos, et al.
Publicado: (2015)

Transurethral ethanol ablation for symptomatic benign prostatic hyperplasia
por: Gautam, Gagan, et al.
Publicado: (2007)

Role of the JNK Pathway in Bladder Cancer
por: Lee, Eun Hye, et al.
Publicado: (2022)

Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study
por: Shim, Sung Ryul, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4ln8cj3j5aj0cbd8r9mog2hm9n